Comment on

• Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

  Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR. Devinsky O, et al. Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24. Lancet Neurol. 2016. PMID: 26724101 Clinical Trial.
• Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases.

  Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, Laux L, Marsh ED. Gofshteyn JS, et al. J Child Neurol. 2017 Jan;32(1):35-40. doi: 10.1177/0883073816669450. Epub 2016 Sep 29. J Child Neurol. 2017. PMID: 27655472
• Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

  Devinsky O, Cross JH, Wright S. Devinsky O, et al. N Engl J Med. 2017 Aug 17;377(7):699-700. doi: 10.1056/NEJMc1708349. N Engl J Med. 2017. PMID: 28813226 No abstract available.